

**Table 4.4**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for CaD Participants Who Did Not Report a Prevalent Condition at Baseline**

Data as of: September 30, 2015; Events through September 30, 2015

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number randomized</b>	36282	5153	8269	16519	6341
<b>Mean follow-up (months)</b>	172.5	184.9	182.9	172.2	149.3
<b>Hospitalizations</b>					
Ever	25795 (4.95%)	2936 (3.70%)	5300 (4.20%)	12357 (5.21%)	5202 (6.59%)
Two or more	18058 (3.46%)	1767 (2.23%)	3458 (2.74%)	8906 (3.76%)	3927 (4.98%)
<b>Other</b>					
DVT <sup>1</sup>	888 (0.17%)	63 (0.08%)	152 (0.12%)	432 (0.19%)	241 (0.32%)
Pulmonary embolism	685 (0.13%)	58 (0.07%)	131 (0.10%)	365 (0.16%)	131 (0.17%)
Diabetes (treated)	5349 (1.06%)	830 (1.07%)	1248 (1.03%)	2507 (1.10%)	764 (1.01%)
Gallbladder disease <sup>2,3</sup>	2410 (1.12%)	355 (1.03%)	591 (1.14%)	1116 (1.18%)	348 (1.00%)
Hysterectomy	1726 (0.56%)	269 (0.58%)	471 (0.60%)	782 (0.56%)	204 (0.46%)
Glaucoma <sup>3</sup>	3570 (1.45%)	389 (1.01%)	751 (1.28%)	1702 (1.55%)	728 (1.83%)
Osteoporosis <sup>3</sup>	6835 (2.81%)	717 (1.87%)	1333 (2.28%)	3299 (3.05%)	1486 (3.83%)
Osteoarthritis <sup>4</sup>	10772 (3.19%)	1774 (2.86%)	2669 (2.97%)	4849 (3.36%)	1480 (3.57%)
Rheumatoid arthritis <sup>3</sup>	1773 (0.72%)	257 (0.68%)	405 (0.70%)	798 (0.73%)	313 (0.77%)
Intestinal polyps	8944 (1.84%)	1410 (1.83%)	2276 (1.89%)	4107 (1.87%)	1151 (1.64%)
Lupus	556 (0.11%)	79 (0.10%)	132 (0.10%)	247 (0.10%)	98 (0.12%)
Kidney stones <sup>3,4</sup>	818 (0.32%)	111 (0.29%)	180 (0.30%)	383 (0.34%)	144 (0.34%)
Cataracts <sup>3,4</sup>	10522 (4.69%)	809 (2.12%)	2040 (3.54%)	5602 (5.64%)	2071 (7.13%)
Hypertension treated w/pills	13288 (3.52%)	1927 (2.96%)	3149 (3.23%)	6164 (3.74%)	2048 (4.14%)
COPD <sup>5</sup>	1460 (0.98%)	143 (0.65%)	328 (0.94%)	797 (1.19%)	192 (0.83%)
Macular degeneration <sup>6</sup>	3824 (0.68%)	245 (0.28%)	579 (0.43%)	1999 (0.79%)	1001 (1.17%)
Alzheimer's disease <sup>6</sup>	2787 (0.49%)	120 (0.14%)	319 (0.23%)	1431 (0.56%)	917 (1.07%)
Parkinson's disease <sup>6</sup>	492 (0.09%)	40 (0.05%)	107 (0.08%)	253 (0.10%)	92 (0.11%)

<sup>1</sup> Inpatient DVT only.

<sup>2</sup> "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

<sup>3</sup> Data not collected for the WHI Extension Studies 2005-2015.

<sup>4</sup> These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>5</sup> Data only collected during the WHI Extension Study 2010-2015.

<sup>6</sup> Data only collected during the WHI Extension Studies 2005-2015.

**Table 4.4 (continued)**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for CaD Participants Who Did Not Report a Prevalent Condition at Baseline**

Data as of: September 30, 2015; Events through September 30, 2015

Outcomes	Race/Ethnicity					
	American Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latino	White	Unknown
<b>Number randomized</b>	149	721	3315	1502	30155	440
<b>Mean follow-up (months)</b>	159.5	164.6	159.8	150.4	175.4	157.5
<b>Hospitalizations</b>						
Ever	98 (4.95%)	405 (4.09%)	2209 (5.01%)	814 (4.32%)	21971 (4.98%)	298 (5.16%)
Two or more	71 (3.59%)	237 (2.40%)	1506 (3.41%)	468 (2.49%)	15580 (3.53%)	196 (3.39%)
<b>Other</b>						
DVT <sup>1</sup>	6 (0.31%)	2 (0.02%)	98 (0.23%)	20 (0.11%)	752 (0.18%)	10 (0.18%)
Pulmonary embolism	4 (0.20%)	1 (0.01%)	61 (0.14%)	12 (0.06%)	599 (0.14%)	8 (0.14%)
Diabetes (treated)	25 (1.34%)	111 (1.18%)	659 (1.66%)	279 (1.57%)	4194 (0.98%)	81 (1.49%)
Gallbladder disease <sup>2,3</sup>	10 (1.25%)	36 (0.82%)	165 (0.79%)	120 (1.51%)	2053 (1.15%)	26 (1.04%)
Hysterectomy	4 (0.49%)	25 (0.39%)	101 (0.53%)	55 (0.52%)	1524 (0.57%)	17 (0.51%)
Glaucoma <sup>3</sup>	20 (2.00%)	56 (1.20%)	443 (2.06%)	171 (1.70%)	2850 (1.38%)	30 (1.07%)
Osteoporosis <sup>3</sup>	27 (2.70%)	148 (3.16%)	394 (1.78%)	282 (2.91%)	5907 (2.91%)	77 (2.78%)
Osteoarthritis <sup>4</sup>	53 (4.04%)	221 (2.98%)	897 (3.25%)	479 (3.62%)	8982 (3.16%)	140 (3.56%)
Rheumatoid arthritis <sup>3</sup>	17 (1.83%)	28 (0.60%)	288 (1.35%)	136 (1.38%)	1279 (0.62%)	25 (0.90%)
Intestinal polyps	42 (2.30%)	149 (1.64%)	876 (2.12%)	291 (1.62%)	7486 (1.82%)	100 (1.88%)
Lupus	5 (0.26%)	4 (0.04%)	63 (0.14%)	22 (0.12%)	455 (0.10%)	7 (0.12%)
Kidney stones <sup>3,4</sup>	7 (0.69%)	18 (0.37%)	73 (0.32%)	46 (0.46%)	666 (0.31%)	8 (0.27%)
Cataracts <sup>3,4</sup>	50 (5.35%)	168 (3.99%)	866 (4.22%)	419 (4.41%)	8893 (4.77%)	126 (4.83%)
Hypertension treated w/pills	43 (3.38%)	241 (3.49%)	996 (4.30%)	552 (3.79%)	11319 (3.46%)	137 (3.65%)
COPD <sup>5</sup>	7 (1.23%)	13 (0.43%)	102 (0.77%)	38 (0.62%)	1283 (1.04%)	17 (0.97%)
Macular degeneration <sup>6</sup>	17 (0.76%)	41 (0.37%)	167 (0.34%)	101 (0.45%)	3467 (0.74%)	31 (0.47%)
Alzheimer's disease <sup>6</sup>	7 (0.31%)	30 (0.27%)	231 (0.47%)	95 (0.42%)	2399 (0.51%)	25 (0.38%)
Parkinson's disease <sup>6</sup>	0 (0.00%)	5 (0.05%)	32 (0.07%)	13 (0.06%)	437 (0.09%)	5 (0.08%)

<sup>1</sup> Inpatient DVT only.

<sup>2</sup> "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

<sup>3</sup> Data not collected for the WHI Extension Studies 2005-2015.

<sup>4</sup> These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>5</sup> Data only collected during the WHI Extension Study 2010-2015.

<sup>6</sup> Data only collected during the WHI Extension Studies 2005-2015.